Trial Profile
A Randomized, Double-masked, Active-controlled, Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Registrational; Therapeutic Use
- Acronyms EXCITE
- Sponsors Novartis
- 15 Aug 2014 New trial record
- 24 Apr 2008
- 04 Oct 2007